allopurinol accord 300 mg tabletes
accord healthcare b.v., netherlands - allopurinols - tablete - 300 mg
xeljanz
pfizer europe ma eeig - tofacitinibs - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 un 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
zenapax
roche registration ltd. - daclizumab - graft rejection; kidney transplantation - imūnsupresanti - zenapax ir indicēts orgānu akūtu atteikuma de novo allogenic nieru transplantācijas profilaksei un ir jālieto kopā ar imunitāti nomācošu režīms, ieskaitot cyclosporine un kortikosteroīdi pacientiem, kuriem nav imunizēti augsti.
mavenclad
merck europe b.v. - kladribīns - multiplā skleroze - imūnsupresanti - pieaugušiem pacientiem ar augsti aktīvo recidivējošo multiplo sklerozi (ms), kā definēts klīniskās vai attēlveidošanas īpašībās.
arduan 4 mg pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
gedeon richter plc., hungary - pipekuronija bromīds - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 4 mg
lidaprim forte 800 mg/160 mg apvalkotās tabletes
rokitan gmbh, austria - trimethoprimum, sulfametrolum - apvalkotā tablete - 800 mg/160 mg
methotrexate "ebewe" 5 mg tabletes
sandoz d.d., slovenia - metotreksāts - tablete - 5 mg
methotrexate "ebewe" 2,5 mg tabletes
sandoz d.d., slovenia - metotreksāts - tablete - 2,5 mg
metex 30 mg šķīdums injekcijām pildspalvveida pilnšļircē
medac gesellschaft für klinische spezialpräparate mbh, germany - metotreksāts - Šķīdums injekcijām pildspalvveida pilnšļircē - 30 mg/0,60 ml
metex 20 mg šķīdums injekcijām pildspalvveida pilnšļircē
medac gesellschaft für klinische spezialpräparate mbh, germany - metotreksāts - Šķīdums injekcijām pildspalvveida pilnšļircē - 20 mg/0,40 ml